Pulmonary arterial hypertension ambrisentan

Galie N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension results of the ambrisentan in pulmonary arterial hypertension. Randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 117(23) 3010-19. 

Ambrisentan is a powerful receptor antagonist that is clinically used for the treatment of pulmonary arterial hypertension. Very recently, Shi s group has applied his methodology to the epoxidation of 3,3-diphenylacrylate 69, which was transformed in four steps into (-l-)-ambrisentan in 53% overall yield and can be carried out in large scale (120g) (Scheme 12.15) [106]. 

The clinical pharmacology, use, and adverse effects of ambrisentan in the management of pulmonary artery hypertension have been reviewed [75 ]. The adverse effects of ambrisentan include peripheral edema, nasal congestion, palpitation, flushing, nasopharyngitis, and sinusitis. In placebo-controlled trials lasting up to 12 weeks the incidence of liver enzyme function abnormalities is lower with ambrisentan than with placebo. 

Liver The availability of ambrisentan in patients with pulmonary artery hypertension who have previously discontinued other endothelin receptor antagonists because of liver function abnormalities provides an important option for patients who have had adverse reactions to bosentan or sitaxsentan [76 ]. Ambrisentan is a... 

Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008 30(5) 825-33. 

McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin W, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009 135(1) 122-9. 

Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin W, Roecker EB, Harrison BC, Despain D, Dufton C. Longterm ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54(21) 1971-81. 

Liew HM, Morris-Jones R, EHaz-Gano S, Bashir S. PseudofoUiculitis barbae induced by oral minoxidil. Qin Exp Dermatol 2012 37 800-1. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Qinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013 48 27-34. 

Ben-YAuda O, Pizzuti D, Brown A, Uttman M, Gillies H, Henig N, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am CoU Cardiol 2012 60 80-1. 

---